Leech Pancreatic Trypsin Inhibitor Variant (LPTI-2)
Bovine pancreatic trypsin inhibitor (Kunitz)-family homolog identified in Hirudo medicinalis sialotranscriptome — sister to LPTI / LCI.
Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Bovine pancreatic trypsin inhibitor (Kunitz)-family homolog identified in Hirudo medicinalis sialotranscriptome — sister to LPTI / LCI.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
Clinical translation limit
This Kunitz-domain inhibitor variant has not been clinically translated. No FDA-approved derivative exists; the broader Kunitz class includes aprotinin, which is unrelated and derived from bovine pancreas.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Molecular weight
- 6,500 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2018
Biological Targets
- → trypsin
- → chymotrypsin
- → kallikrein
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.